Open-label, Randomized, Single-dose, Cross-over Study to Evaluate the Influence of Dietary Habits on the Pharmacokinetics, Safety, and Tolerability of a 120 mg Dose and to Assess the Relative Bioavailability of a 240 mg Dose of Nifurtimox Tablets Administered to Adult Male and Female Patients With Chagas' Disease
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 19 Dec 2018
At a glance
- Drugs Nifurtimox (Primary)
- Indications Chagas disease
- Focus Pharmacokinetics
- Sponsors Bayer
- 10 Dec 2018 Planned End Date changed from 28 Jun 2019 to 29 Aug 2019.
- 10 Dec 2018 Planned primary completion date changed from 21 May 2019 to 9 Aug 2019.
- 10 Dec 2018 Planned initiation date changed from 4 Mar 2019 to 1 Apr 2019.